Latest diabetic neuropathy Stories
DOYLESTOWN, Pa., April 30 /PRNewswire-FirstCall/ -- Quigley Pharma Inc., www.quigleyco.com, a wholly-owned subsidiary of The Quigley Corporation (Nasdaq: QGLY) announced today that their recently completed Phase 2 double-blinded, placebo-controlled, clinical trial of diabetic peripheral neuropathy, demonstrated a significant improvement in two key measures of distal sensory nerve function in the group treated with QR333. The compound was applied topically to the feet of subjects suffering...
Evaluation of Neurologic Safety following Treatment with Qutenza(TM) (NGX-4010) Identification of Impact of PHN and PDN on Health Care Costs SAN MATEO, Calif., April 29 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today the presentation of two posters at the 61st Annual American Academy of Neurology (AAN) meeting in Seattle, Washington. These posters, titled...
Qutenza(TM) Receives Positive Committee Recommendation in European Union Corporate Highlights: - CHMP issued positive opinion recommending approval of Qutenza(TM) (formerly NGX-4010) for treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain - Qutenza NDA accepted for review by U.S. FDA for PHN Upcoming 2009 Milestones: - European commercial partnership for Qutenza anticipated first half of 2009 - European...
Broad Label Indicated for Peripheral Neuropathic Pain in Non-Diabetic Adults Conference Call Scheduled Friday, March 20 at 9am ET SAN MATEO, Calif., March 19 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of...
Transplanting cells that replenish blood vessels can also restore nerve function in an animal model of diabetic neuropathy, Emory researchers have found.The results are described online this week in the journal Circulation.The majority of people with diabetes have some form of neuropathy--damage to the peripheral nerves that can cause a loss of sensation in hands, arms, feet or legs. The damage, caused by high blood sugar, occurs gradually and in advanced cases can lead to amputation....
Scientist cautions that activities should be supervised closely by a medical professionalMore than 20 million Americans are living with diabetes, and that number is expected to increase by more than 5 million by 2010. One complication related to diabetes, Diabetic Peripheral Neuropathy, (DM+PN), can cause individuals to develop foot ulcers and, in extreme cases, amputation might be necessary. Previously, doctors and scientists have recommended that individuals with this complication stay off...
It's now easier to know who should be tested for a common nerve disorder, when they should be tested, and how.Two new studies from Louisiana State University recommend new testing guidelines for neuropathy -- a degenerative nerve disorder. Researchers say a combination of certain screening blood tests and other specialized testing brings definitive information for certain forms of the disorder, while nerve biopsies may not be as useful in certain cases."There are many people with a neuropathy...
DOYLESTOWN, Pa., Nov. 12 /PRNewswire-FirstCall/ -- Quigley Pharma Inc., a wholly-owned subsidiary of The Quigley Corporation announced today that the last subject in the Phase IIb Study is scheduled to complete treatment on November 25, 2008. This will effectively move the study to the final stage of data collection, evaluation and study conclusions. The Company, after collecting all the patient information from 21 Study centers and conferring with its panel of experts on the data, will...
Sangamo BioSciences, a developer of novel DNA-binding proteins for therapeutic gene regulation and modification, has announced top-line data from its SB-509-601 clinical trial, one of Sangamo's three Phase II clinical studies from its ZFP therapeutic program to develop SB-509 for diabetic neuropathy. The study is a double-blind, placebo-controlled, repeat-dosing multi- center study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics...
RICHMOND, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. announced today top-line data from its SB-509-601 clinical trial, one of Sangamo's three Phase 2 clinical studies from its ZFP Therapeutic(TM) program to develop SB-509 for diabetic neuropathy (DN). The data demonstrate that repeat administration of the drug is well tolerated in subjects with mild to moderate DN. However, no significant differences were observed between the SB-509 and placebo treated subjects in...
